Anti-Cancer/ Oncology API Products
Explorar Anti-Câncer / Oncologia Products
Abiraterona Acetato
Anti-Câncer / Oncologia
Adagrasib
Anti-Câncer / Oncologia
Apalutamide (Amorphous & Form B)
Anti-Câncer / Oncologia
Azacitidina
Anti-Câncer / Oncologia
Cloridrato De Bendamustina
Anti-Câncer / Oncologia
Bortezomibe
Anti-Câncer / Oncologia
Cabazitaxel
Anti-Câncer / Oncologia
Cabozantinib S-Malate
Anti-Câncer / Oncologia
Capecitabina
Anti-Câncer / Oncologia
Carfilzomib
Anti-Câncer / Oncologia
Darolutamide
Anti-Câncer / Oncologia
Dasatinibe
Anti-Câncer / Oncologia
Decitabina
Anti-Câncer / Oncologia
Deucravacitinib
Anti-Câncer / Oncologia
Fruquintinib
Anti-Câncer / Oncologia
Gemcitabine Hydrochloride
Anti-Câncer / Oncologia
Granisteron
Anti-Câncer / Oncologia
Lenalidomida
Anti-Câncer / Oncologia
Lenvatinib Mesylate (Form C & MIBK Solvate)
Anti-Câncer / Oncologia
Lomustina
Anti-Câncer / Oncologia
Midostaurin
Anti-Câncer / Oncologia
Cloridrato De Nilotinibe
Anti-Câncer / Oncologia
Niraparib Tosylate
Anti-Câncer / Oncologia
Olaparib (Form A)
Anti-Câncer / Oncologia
Palbociclibe
Anti-Câncer / Oncologia
Pazopanib
Anti-Câncer / Oncologia
Dissódio Pemetrexede (hepta-hidratado)
Anti-Câncer / Oncologia
Pirtobrutinib
Anti-Câncer / Oncologia
Pomalidomida
Anti-Câncer / Oncologia
Relugolix
Anti-Câncer / Oncologia
Ripretinib
Anti-Câncer / Oncologia
Tucatinib
Anti-Câncer / Oncologia
Venetoclax
Anti-Câncer / Oncologia
Zanubrutinib
Anti-Câncer / Oncologia
Ácido Zoledrônico
Anti-Câncer / Oncologia
Lenvatinib Mesylate (Form-C)
Anti-Câncer / Oncologia
Cabozantinib HCl
Anti-Câncer / Oncologia
Mesilato De Eribulina
Anti-Câncer / Oncologia
Enzalutamida
Anti-Câncer / Oncologia
Ritlecitinib
Anti-Câncer / Oncologia
Dr. Reddys Portfolio of Anti-cancer APIs
We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.
Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.
We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.
USPs of our Anti-cancer APIs
- QbD approach for an efficient process & high-quality output
- Availability of APIs in various forms.
- cGMP API manufacturing facility - Successfully inspected by international regulatory authorities.
- GTIs & impurities are controlled below the TTC limit & ICH limits, respectively.
- Formulation dossier filed across all major markets.
- Regulatory filing available across the globe.
- Completely backward integrated on the Key starting materials to ensure uninterrupted supplies.
- Adequate capacity to meet the global demands.
- KSM suppliers with timely deliveries and adherence to stringent specifications.
- Process safety management guidelines are implemented to enable a sustainable product supply.
- IP-Compliant API that meets regulatory requirements.
Dr. Reddy, is well-positioned to meet the global demand for Anti-cancer/Oncology APIs. As for many of our APIs. the key starting materials (KW) are backward integrated today. We've also established strategic solid sourcing and logistics partnerships and work closely with our customers to successfully manage Me capacities of our manufacturing units ahead of launches.
To know more about our end-to-end solutions for Anti-cancer/Oncology APIs formulations and Dosage forms. Check out our board portfolio of Anti-cancer/Oncology APIs here (Link) (or) Contact us at [email protected]
Explorar other Therapeutic categories.
Category-Oncology FAQ
- The oncology API market aims to share and reshape the flow of the pharmaceutical industry's demand.
- The global oncology API market is expected to exhibit strong growth from 2022 to 2026.
- The cancer API Market is expected to reach USD 1,48,545.23 Million by 2030 at 7.10% CAGR during the forecast period 2022-2030.
Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Oncology drugs include a range of different types of medications, such as chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies.
- Thalidomide Analogues
- Alkalyting agents
- Androgen receptors
- Folate Analog Metabolic
- Nucleoside
- Metabolic
- Microtubule
Alkylating agents - cross-linking of DNA strands, inhibiting DNA replication and RNA transcription. Some antimetabolites - Interfere with DNA or RNA synthesis. Alkaloids bind to tubulin and inhibit the formation of microtubules, causing metaphase arrest, and camptothecins inhibit topoisomerase. Others - induces cell death or differentiation.
The knock of the API sector is having a significant effect on the overall cancer API market growth. The Oncology API market has undergone immense changes due to supply chain disruption caused by COVID-19. COVID-19 has disrupted the pharmaceutical industry's production and supply chain.
The global oncology drugs market size was valued at 135.4 Billion in 2020 and is projected to reach 274.4 billion by 2030, registering a CAGR of 7.5% from 2021 to 2030.
Aviso legal
Nenhuma informação neste site, incluindo qualquer referência a qualquer produto ou serviço, constitui uma oferta de venda ou pode ser interpretada como representando uma oferta de venda. Produtos protegidos por patentes válidas não são oferecidos ou fornecidos para uso comercial. No entanto, em certos casos, a critério exclusivo do Dr. Reddy e sujeito a requisitos legais locais, as quantidades de pesquisa de tais produtos podem ser oferecidas para fins de submissões regulatórias sob a Seção 107A da Lei de Patentes da Índia (isenção Bolar), onde quer que tais isenções regulatórias existam. Os compradores devem fazer sua avaliação independente do produto ou serviço, incluindo o cenário de patentes em seus respectivos mercados e serão responsáveis por todas as responsabilidades relacionadas a patentes. O Dr. Reddy se isenta de todas as garantias, expressas ou implícitas, incluindo, entre outras, garantias de comercialização, adequação a uma finalidade específica e não violação.